On Assignment Rebrands Its U.S. Clinical Research Division

On Assignment Rebrands Its U.S. Clinical Research Division

CALABASAS, Calif., January 6, 2012 -- On Assignment, Inc. (NASDAQ: ASGN), a leading global provider of diversified professional staffing solutions, announced today that they have rebranded their U.S. clinical research division under the name Valesta Clinical Research Solutions.

This change was made to best promote the company's global presence in clinical research and their range of service offerings - from contract and direct hire placements to functional outsourcing for clinical trials. The new name also leverages the strength of the existing Valesta clinical research brand within Western Europe - a company acquired by On Assignment in February 2011.

 "By unifying the brand we can effectively communicate our enhanced global services that offer new ways to meet the needs of our customers," said Emmett McGrath, president of On Assignment's Life Sciences and Allied Healthcare divisions. "We are excited about the new opportunities this brings for both our clients and employees."

Valesta Clinical Research Solutions operates in the United States, Belgium, Netherlands, and Spain. Learn more at www.valesta.com.

 

About On Assignment
On Assignment, Inc. (NASDAQ: ASGN), is a leading global provider of highly skilled, hard-to-find professionals in the growing life sciences, healthcare, and technology sectors, where quality people are the key to success. The company goes beyond matching résumés with job descriptions to match people they know into positions they understand for temporary, contract-to-hire, and direct hire assignments. Clients recognize On Assignment for their quality candidates, quick response, and successful assignments. Professionals think of On Assignment as career-building partners with the depth and breadth of experience to help them reach their goals.
On Assignment was founded in 1985 and went public in 1992. The corporate headquarters are located in Calabasas, California, with a network of approximately 78 branch offices throughout the United States, Canada, United Kingdom, Netherlands, Ireland, Spain, and Belgium. Additionally, physician placements are made in Australia and New Zealand. To learn more, visit www.onassignment.com.


 

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.